A mitochondria-targeted peptide blunted semaglutide-linked lean-mass loss — in aged mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

GLP-1 drugs take weight off — and some of what comes off is muscle. In very old mice, a peptide built to prop up aging mitochondria appears to protect that muscle, at least on the company's own numbers.

What did PTC-2105 do on its own?

In aged, high-fat-fed mice, PTC-2105 monotherapy reversed the terminal lean-mass trajectory — from a decline of -0.002 grams per week on saline to a net gain of +0.005 grams per week. The company also tracks a single long-lived animal, 'Speedy,' treated from about 80 weeks of age and now turning 170 weeks, more than 7.6 months past the last untreated control at 137 weeks. A single mouse is an anecdote with a name, not a survival result — the cohort numbers are the data, and even those are company-reported and not yet peer-reviewed.

What happened alongside semaglutide?

In a second high-fat cohort, semaglutide alone produced the steepest terminal lean-mass decline (-0.055 g per week) and was associated with shorter survival (p=0.038), while PTC-2105 monotherapy avoided that decline (+0.009 g per week). Co-administration of PTC-2105 with semaglutide at 10 and 25 mg per kg, once weekly, reduced late-life lean-mass loss relative to semaglutide alone (+0.126 and -0.011 g per week versus -0.055). If that pattern held in people it would matter: lean-mass loss on GLP-1 therapy is a real clinical concern in older patients. Whether it holds in people is exactly what has not been tested.

What is PTC-2105, and what happens next?

PTC-2105 is a once-weekly, subcutaneously injected geropeptide from Eos's MitoXcel platform. Per the company, it targets the age-related decline in mitochondrial membrane potential through two mechanisms: enhancing mitochondrial efficiency in aging cells and selectively eliminating senescent cells. It is the company's lead candidate for sarcopenia and sarcopenic obesity in elderly patients. The data will be presented at the 19th Sarcopenia, Cachexia & Wasting Disorders conference on December 11, 2026, upgraded from a poster to a plenary Rapid Fire session. Eos also notes a merger with Pulmatrix, Inc. anticipated to close in Q4 2026. The company's own disclaimer is the correct frame: all data are preclinical, in mice, and results in mice may not translate to humans.

Where the evidence stands

• Established: Lean-mass loss accompanies GLP-1 weight loss and is a particular concern in older adults; mitochondrial membrane potential declines with age; sarcopenia has no broadly effective drug therapy.
• Preliminary: PTC-2105 lean-mass and semaglutide-combination findings: company-reported preclinical data in aged high-fat-fed mice (GlobeNewswire, November 9, 2026), scheduled for conference presentation December 11, 2026. Not peer-reviewed, not independently replicated.
• Absent: Human evidence of any kind — PTC-2105 has not been tested for lifespan, muscle or any outcome in people and is not approved by the FDA or any regulator for any indication.